| If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| | | ![]() DG DISPATCH - AAP: New Formulations Of Antiepileptic Drugs Available For Children By Lara Pullen Special to DG News
CHICAGO, IL -- November 2, 2000 -- Epilepsy affects up to 1 percent of the United States population and new formulations of older antiepileptic drugs provide an increased number of therapeutic tools in the treatment of this common neurological disease. At the American Academy of Pediatrics (AAP) Annual Meeting, Dr. James W. Wheless of the University of Texas, Houston, presented an overview of new formulations of antiepileptics and their role in the treatment of children with epilepsy. Tegretol-XR® and Carbatrol® are new formulations of carbamezapine that allow for twice daily dosing, while at the same time minimizing drug toxicity and improving efficacy. The application of extended release technology provides for steady levels of the drug and reduces the number of doses per day. Since noncompliance is the number-one cause of breakthrough seizures, the twice-daily dosing improves patient compliance and, therefore treatment, efficacy. Topiramate sprinkle capsules (Topamax®) and lamotrigine chewable dispersible tablets (Lamictal®) can be useful for the treatment of younger patients who will not yet swallow tablets. Diazepam (Diastat®) now comes in a rectal gel formulation that has proven useful for the treatment of acute seizure exacerbations. Intravenous valproate (Depacon®) and fosphenytoin (Cerebyx®) allow for the treatment of acute seizures without significant peripheral venous side effects.
|